| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Knight Therapeutics Inc (TO: GUD)
GUD Technical Analysis
5
| As on 2nd Jul 2025 GUD STOCK Price closed @ 6.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.63 & Strong Buy for SHORT-TERM with Stoploss of 5.43 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GUDSTOCK Price
| Open | 5.81 | Change | Price | % |
| High | 6.02 | 1 Day | 0.17 | 2.92 |
| Low | 5.81 | 1 Week | 0.15 | 2.56 |
| Close | 6.00 | 1 Month | 0.23 | 3.99 |
| Volume | 50691 | 1 Year | 0.82 | 15.83 |
| 52 Week High 6.27 | 52 Week Low 5.11 | ||||
TO Canada Most Active Stocks
| YRI | 7.89 | 0.13% |
| TD | 101.10 | 0.94% |
| TRP | 65.19 | -1.94% |
| UEX | 0.50 | 16.28% |
| CVE | 19.39 | 4.64% |
| SU | 52.00 | 1.94% |
| WCP | 9.22 | 0.77% |
| ENB | 60.85 | -1.46% |
| SJR-B | 40.48 | 0.02% |
| BCE | 31.04 | 2.78% |
TO Canada Top Gainers Stocks
TO Canada Top Losers Stocks
| GUD Daily Charts |
GUD Intraday Charts |
Whats New @ Bazaartrend |
GUD Free Analysis |
|
|
GUD Important Levels Intraday
| RESISTANCE | 6.40 |
| RESISTANCE | 6.27 |
| RESISTANCE | 6.19 |
| RESISTANCE | 6.11 |
| SUPPORT | 5.89 |
| SUPPORT | 5.81 |
| SUPPORT | 5.73 |
| SUPPORT | 5.60 |
GUD Forecast July 2025
| 4th UP Forecast | 7.31 |
| 3rd UP Forecast | 6.89 |
| 2nd UP Forecast | 6.63 |
| 1st UP Forecast | 6.37 |
| 1st DOWN Forecast | 5.63 |
| 2nd DOWN Forecast | 5.37 |
| 3rd DOWN Forecast | 5.11 |
| 4th DOWN Forecast | 4.69 |
GUD Weekly Forecast
| 4th UP Forecast | 6.39 |
| 3rd UP Forecast | 6.26 |
| 2nd UP Forecast | 6.19 |
| 1st UP Forecast | 6.11 |
| 1st DOWN Forecast | 5.89 |
| 2nd DOWN Forecast | 5.81 |
| 3rd DOWN Forecast | 5.74 |
| 4th DOWN Forecast | 5.61 |
GUD Forecast2025
| 4th UP Forecast | 8.66 |
| 3rd UP Forecast | 7.81 |
| 2nd UP Forecast | 7.28 |
| 1st UP Forecast | 6.75 |
| 1st DOWN Forecast | 5.25 |
| 2nd DOWN Forecast | 4.72 |
| 3rd DOWN Forecast | 4.19 |
| 4th DOWN Forecast | 3.34 |
Knight Therapeutics Inc ( TO Canada Symbol : GUD )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GUD Business Profile
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada. Address: 3400 De Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service